Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

The secrets of idiopathic pulmonary fibrosis (IPF) are written in its very name. Idiopathic refers to a disease of unknown ...

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

New research shows that treatment timing is key when it comes to deciding between immunotherapy and chemoimmunotherapy for ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...